Cytosorbents Crp (CTSO) revenue breakdown
By product, CytoSorb sales is the largest at 85% of fiscal 2023 revenue; Grant income grew fastest, 20% a year over 6 years.
By region, Germany is the largest at 58% of fiscal 2018 revenue; All other countries grew fastest, 59% a year over 2 years.
Revenue by product
Fiscal years, as Cytosorbents Crp reports them in its 10-K filings; fiscal 2023 total $36M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|---|
| CytoSorb sales | $13M | $20M | $23M | $39M | $40M | $29M | $31M | 85% |
| Grant income | $2M | $2M | $2M | $2M | $3M | $5M | $5M | 14% |
| Other product sales | $126,900 | $109,029 | $220,100 | $110,400 | $111,867 | $787,201 | $69,685 | 0% |
Revenue by region
Fiscal years, as Cytosorbents Crp reports them in its 10-K filings; fiscal 2018 total $20M.
| Regions | 2016 | 2017 | 2018 | Share |
|---|---|---|---|---|
| Germany | $5M | $8M | $12M | 58% |
| All other countries | $3M | $5M | $8M | 41% |
| United States | — | $126,900 | $95,500 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CTSO.
Open CTSO in InvestinglyQuestions
Where does Cytosorbents Crp make its money?
In fiscal 2023, by product: CytoSorb sales $31M, Grant income $5M, Other product sales $69,685.
From Cytosorbents Crp's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.